Global Leading Market Research Publisher QYResearch announces the release of its latest report “Immuno-oncology Diagnosis – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.
The clinical success of checkpoint inhibitors—PD-1/PD-L1 and CTLA-4 antibodies that have transformed the treatment paradigm for melanoma, non-small cell lung cancer, and multiple additional tumor types—has created a diagnostic imperative of commensurate scale: for each patient considered for immunotherapy, a constellation of predictive biomarkers must be interrogated with quantitative precision to determine the probability of response, stratification into approved indications, and risk of immune-related adverse events. The therapeutic revolution has thus generated a diagnostic revolution in its wake, as immuno-oncology diagnostics have evolved from simple immunohistochemical staining for a single protein biomarker into a comprehensive system of molecular, genomic, and algorithmic technologies that together constitute the patient selection, efficacy prediction, and dynamic monitoring infrastructure upon which the entire immunotherapeutic enterprise depends. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Immuno-oncology Diagnosis market, delivering the strategic intelligence on PD-L1 companion diagnostics, tumor mutational burden testing, liquid biopsy for immunotherapy monitoring, microsatellite instability assessment, and multi-omic immune profiling that pharmaceutical executives, diagnostic company strategists, clinical laboratory directors, and healthcare investors require to navigate the diagnostic gateway to cancer’s most transformative therapeutic modality.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6698023/immuno-oncology-diagnosis
The global market for Immuno-oncology Diagnostics was estimated to be worth USD 9,003 million in 2025 and is projected to reach USD 20,550 million by 2032, advancing at an exceptional CAGR of 12.6% from 2026 to 2032. This more-than-doubling of market value over seven years reflects the structurally determined expansion of immunotherapeutic indications across an ever-broadening array of cancer types, the progressive sophistication of predictive biomarker strategies from single-analyte immunohistochemistry toward multi-omic, algorithmically integrated composite biomarkers, and the technology-driven migration from tissue-based, single-time-point testing toward non-invasive, serial liquid biopsy monitoring capable of detecting acquired resistance and immunotherapeutic response dynamics in near real time.
Product Definition: The Diagnostic Architecture for Cancer Immunotherapy
Immuno-oncology diagnostics refers to a comprehensive system of precise detection and evaluation technologies built around tumor immunotherapy. The core analytical portfolio encompasses immunohistochemistry (IHC) for PD-L1 protein expression assessment using validated antibody clones and standardized scoring algorithms, molecular diagnostics including polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) for specific genetic alterations, next-generation sequencing (NGS) for tumor mutational burden (TMB) quantification and comprehensive genomic profiling of immuno-oncology-relevant genes, liquid biopsy for analysis of circulating tumor DNA (ctDNA), circulating tumor cells, and immune cell populations in peripheral blood, and multi-omic integrated analysis combining genomic, transcriptomic, proteomic, and immunophenotypic data.
The clinical function of cancer immunotherapy diagnostics spans three critical domains: patient screening and selection to identify individuals most likely to derive clinical benefit from specific immunotherapies based on validated predictive biomarker thresholds, efficacy prediction and prognosis to stratify patients by expected treatment outcomes, and dynamic monitoring to detect treatment response, acquired resistance, and disease progression through serial assessment of circulating biomarkers. This comprehensive diagnostic framework enables integrated, personalized treatment decisions encompassing diagnosis, therapeutic selection, and longitudinal efficacy evaluation, positioning immuno-oncology diagnostics as a crucial entry-point technology within the broader precision medicine ecosystem.
Strategic Industry Dynamics: The Drug-Diagnostic Co-Development Model and the Multi-Omic Evolution
An exclusive analytical perspective reveals three structural dynamics that are reshaping the immuno-oncology testing competitive landscape and value chain.
The drug-diagnostic co-development model as competitive moat. The growth logic of immuno-oncology diagnostics is highly dependent on the expansion of tumor immunotherapy. With the continuous expansion of PD-1/PD-L1 inhibitor indications across non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, gastric cancer, esophageal cancer, hepatocellular carcinoma, and multiple additional cancer types, and with the emergence of novel immunotherapeutic modalities including CAR-T cell therapies, bispecific T-cell engager antibodies, and next-generation checkpoint inhibitors targeting LAG-3, TIGIT, and beyond, the demand for precise patient screening and companion diagnostics is expanding commensurately. At the regulatory level, the “drug-diagnostic” collaborative approval model—in which a companion diagnostic is developed and validated alongside its corresponding therapeutic—is being strengthened across FDA, EMA, and NMPA jurisdictions, forming a deep bond between leading diagnostic companies and pharmaceutical partners that creates substantial barriers to entry for competitors lacking these co-development relationships.
The multi-omic evolution from single biomarker to integrated analysis. The industry is upgrading from single biomarker detection—PD-L1 IHC alone—to multi-omics integrated analysis that combines PD-L1 expression, tumor mutational burden, microsatellite instability status, and gene expression signatures into composite predictive algorithms that outperform any single analyte in predicting immunotherapeutic response. This evolution is driving demand for progressively more comprehensive and analytically complex testing platforms.
The liquid biopsy and AI convergence. The combination of liquid biopsy and AI algorithms is driving the trend toward non-invasive, dynamic monitoring capable of detecting acquired resistance, immune-mediated pseudoprogression, and treatment response far earlier than conventional imaging. This significantly improves clinical value and testing frequency, transforming immuno-oncology diagnostics from a one-time pre-treatment assessment into a longitudinal monitoring paradigm that generates recurring revenue per patient.
Technology Challenges: Standardization, Reimbursement, and Clinical Utility
The market faces several technology challenges that shape competitive dynamics. PD-L1 IHC standardization across different antibody clones, staining platforms, and scoring algorithms remains a persistent analytical challenge, with different companion diagnostic assays generating different patient classification results from the same tissue specimen. Reimbursement coverage for advanced genomic profiling and serial liquid biopsy monitoring remains variable across healthcare systems. Demonstrated clinical utility—proving that diagnostic test results change treatment decisions in ways that improve patient outcomes—remains the evidentiary bar for broad adoption.
Competitive Landscape and Market Segments
Key players span global diagnostic leaders and specialized genomics companies: Guardant Health, Foundation Medicine, Illumina, Thermo Fisher Scientific, LabCorp, NeoGenomics, Myriad Genetics, Caris Life Sciences, Roche, BioMérieux, QIAGEN, Chinese diagnostic companies Burning Rock Biotech, Novogene, BGI Genomics, and Asia-Pacific leaders Sysmex, Fujirebio, IMBDx, Seegene, and GeneMatrix.
Segment by Type
Immunohistochemistry: PD-L1 testing; the foundational and dominant near-term modality.
Molecular Diagnostics: PCR and FISH for MSI, TMB, and specific mutations.
High-Throughput Sequencing: Comprehensive genomic profiling; the growth engine.
Liquid Biopsy: ctDNA and circulating tumor cell analysis; the structural growth frontier.
Multi-omics Integrated Analysis: Combined genomic, transcriptomic, and proteomic profiling.
Segment by Application
Research: Pharmaceutical development, biomarker discovery, and clinical trial stratification.
Diagnostics: Clinical patient selection, monitoring, and treatment decision support.
Strategic Outlook
It is expected that the immuno-oncology diagnostic market will continue to maintain medium-to-high-speed growth over the next 5-10 years, becoming one of the most core infrastructures within the precision medicine and cancer treatment ecosystem. The market at USD 9,003 million in 2025 projecting to USD 20,550 million by 2032 reflects the structural expansion of immunotherapy across cancer types, the progressive sophistication of predictive biomarker strategies, and the technology-driven evolution from single-analyte testing toward the integrated, multi-omic, and dynamically monitored diagnostic paradigm that increasingly defines the gateway to cancer’s most effective therapeutic interventions.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
